360 677

Cited 9 times in

Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma

DC Field Value Language
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박예현-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.contributor.author한광협-
dc.date.accessioned2019-07-11T03:10:07Z-
dc.date.available2019-07-11T03:10:07Z-
dc.date.issued2019-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/169863-
dc.description.abstractBACKGROUND: Hepatoma arterial-embolization prognostic (HAP) score and its modifications (modified HAP [mHAP] and mHAP-II), consisting of some or all of the following factors of tumor size, number, alpha-fetoprotein, bilirubin, and serum albumin, have been found to predict outcomes after trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). We investigated the feasibility of using HAP-related risk scores for dynamic risk assessment during repeated TACE. METHODS: A total of 619 HCC patients treated with TACE from two institutions between 2003 and 2010 were included. RESULTS: Patients with A-B class risk scores showed significantly better survival than those with C-D class risk scores at the first (median 43.7 vs. 21.5 months for mHAP-II, 35.2 vs. 10.2 months for mHAP, and 39.8 vs. 18.6 months for HAP; all P < 0.001) and the second rounds of TACE (38.6 vs. 17.2 months for mHAP-II, 30.0 vs. 8.5 months for mHAP, and 32.6 vs. 17.3 months for HAP; all P < 0.001). Sequential assessment of risk scores at the second TACE round was applied for patients with A-B class risk scores at the first TACE round, which further identified two subgroups of A-B and C-D class risk scores with different outcomes (median survival 40.6 vs. 19.6 months for mHAP-II, 31.2 vs. 16.9 months for mHAP, and 35.8 vs. 21.0 months for HAP; all P < 0.001). Compared with mHAP and HAP, mHAP-II showed the highest likelihood ratio (22.61 vs. 14.67 and 13.97, respectively), highest linear trend (24.43 vs. 19.67 and 14.19, respectively), and lowest Akaike information criteria value (1432.51 vs. 3412.29 and 2296.98, respectively). CONCLUSIONS: All HAP-related risk scores dynamically predicted outcomes during repeated TACE. Sequential risk assessment using mHAP-II best identified optimal candidates for repeated TACE.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherBioMed Central-
dc.relation.isPartOfBMC CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleFeasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorYehyun Park-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorKwang-Hyub Han-
dc.contributor.googleauthorJong Eun Yeon-
dc.contributor.googleauthorKwan Soo Byun-
dc.contributor.googleauthorHye Soo Kim-
dc.contributor.googleauthorJi Hoon Kim-
dc.contributor.googleauthorSeung Up Kim-
dc.identifier.doi10.1186/s12885-019-5495-6-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA01575-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA04268-
dc.relation.journalcodeJ00351-
dc.identifier.eissn1471-2407-
dc.identifier.pmid30991968-
dc.subject.keywordHepatocellular carcinoma-
dc.subject.keywordHepatoma arterial-embolization prognostic score-
dc.subject.keywordRisk prediction-
dc.subject.keywordTrans-arterial chemoembolization-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor박예현-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor한광협-
dc.citation.volume19-
dc.citation.number1-
dc.citation.startPage363-
dc.identifier.bibliographicCitationBMC CANCER, Vol.19(1) : 363, 2019-
dc.identifier.rimsid62189-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.